Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
SpyGlass Ophthalmics
AddedFeb 17, 2024
UpdatedJun 18, 2026
SpyGlass Ophthalmics

SpyGlass Ophthalmics

Series B

SpyGlass Ophthalmics: Partnering with NEA to develop novel technologies for improved quality of life.

HQ
Mission Viejo, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

SpyGlass Ophthalmics was founded with the mission to develop novel ophthalmic technologies aimed at enhancing the quality of life. The company collaborates closely with New Enterprise Associates (NEA) to bring innovative solutions to the market, focusing on advanced eye care products and services. Their primary market includes patients requiring cutting-edge ophthalmic treatments and healthcare providers seeking state-of-the-art medical tools.

Notably, SpyGlass Ophthalmics has spun out a subsidiary, SpyGlass Pharma, to further specialize in their technological advancements. The company has secured significant investment from NEA, a prominent venture capital firm. These achievements underscore SpyGlass Ophthalmics' impact in the field of ophthalmology, driving forward new technologies that promise to improve patient outcomes and revolutionize eye care.

SpyGlass Ophthalmics - Similar Companies

Spyglass Pharma logo

Spyglass Pharma

spyglasspharma.com

EyeCyte logo

EyeCyte

eyecyte.com

Ocular Science logo

Ocular Science

ocularscience.com

Ocular Therapeutix logo

Ocular Therapeutix

ocutx.com

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Glaukos logo

Glaukos

glaukos.com

Forsight Vision6 logo

Forsight Vision6

Visiox logo

Visiox

visioxpharma.com

Sight Sciences logo

Sight Sciences

sightsciences.com

Eyebot logo

Eyebot

eyebot.tech

Nexis Vision logo

Nexis Vision

Forsight Labs logo

Forsight Labs

Eye2021 logo

Eye2021

eye2021.com

Optovue logo

Optovue

Clearsight logo

Clearsight

SpyGlass Ophthalmics - Quick Facts

Who are SpyGlass Ophthalmics' competitors?

Companies similar to SpyGlass Ophthalmics include Spyglass Pharma, EyeCyte, Ocular Science and Ocular Therapeutix.

When was SpyGlass Ophthalmics founded?

SpyGlass Ophthalmics was founded in 2019.

Where is SpyGlass Ophthalmics' headquarters located?

SpyGlass Ophthalmics' headquarters is located in Mission Viejo, CA, US.

When was SpyGlass Ophthalmics' last funding round?

SpyGlass Ophthalmics' most recent funding round was for $27.5M (USD) in January 2021.

How much has SpyGlass Ophthalmics raised to-date?

As of Jan 7, 2021, SpyGlass Ophthalmics has raised a total of $27.5M (USD).

How many employees does SpyGlass Ophthalmics have?

SpyGlass Ophthalmics has 8 employees as of Feb 4, 2024.

SpyGlass Ophthalmics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Model
  • Platform
Customer
  • Enterprise
Main Product
  • Eye Care
  • Medical Devices
Tags
  • Consulting
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research